Literature DB >> 15356826

The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting.

N O Akinola1, O Olasode, I A Adediran, O Onayemi, A Murainah, O Irinoye, A A Elujoba, M A Durosinmi.   

Abstract

Total lymphocyte count (TLC) has been recommended as a substitute for CD4 cell count for the management of HIV-infected individuals living in resource-limited settings. To confirm this, 151 TLCs and CD4 cell counts were obtained from 109 patients who had not yet started treatment and analyzed. CD4 cell counts of <200 cells/mm3 were found in 42 cases (37.8%) with TLCs of > or =1200 cells/mm3. Thus, 1 in 3 individuals would have been deprived of needed treatment. Therefore, in this setting, TLC is not a reliable predictor of CD4 cell count in HIV-infected individuals.

Entities:  

Mesh：

Year:  2004        PMID： 15356826     DOI： 10.1086/422722

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  16 in total

1.  Absolute Lymphocyte Count as a Surrogate Marker of CD4 Count in Monitoring HIV Infected Individuals: A Prospective Study.

Authors:  Preeti Balkisanji Agrawal; Sharda Raju Rane; Meenal Vitthal Jadhav
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Total Lymphocyte Count and Haemoglobin Concentration Combined as a Surrogate Marker for Initiating Highly Active Antiretroviral Therapy in a Resource-limited Setting as against CD4 Cell Count.

Authors:  A C Dhamangaonkar; A Mathew; A R Pazare
Journal:  West Indian Med J       Date:  2014-05-08       Impact factor: 0.171

3.  Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: a retrospective evaluation.

Authors:  Yuming Wang; Shuying Liang; Erman Yu; Jinling Guo; Zizhao Li; Zhe Wang; Yukai Du
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

4.  Body mass index, proteinuria and total lymphocyte counts in predicting treatment responses among ART naïve individuals with HIV initiated on antiretroviral treatment in Dar es Salaam, Tanzania, 2019: a cohort study.

Authors:  Patricia Munseri; Lazaro Jassely; Basil Tumaini; Ellen Hertzmark
Journal:  BMJ Open       Date:  2022-06-08       Impact factor: 3.006

5.  Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.

Authors:  Philippa M Musoke; Alicia M Young; Maxensia A Owor; Irene R Lubega; Elizabeth R Brown; Francis A Mmiro; Lynne M Mofenson; J Brooks Jackson; Mary Glenn Fowler; Laura A Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

6.  Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India.

Authors:  S Srirangaraj; D Venkatesha
Journal:  Indian J Med Res       Date:  2012-06       Impact factor: 2.375

7.  Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings.

Authors:  Christian Obirikorang; Lawrence Quaye; Isaac Acheampong
Journal:  BMC Infect Dis       Date:  2012-06-07       Impact factor: 3.090

8.  Utility of total lymphocyte count as a surrogate for absolute CD4 count in the adult Indian HIV population: A prospective study.

Authors:  Suman S Karanth; N R Rau; Anurag Gupta; Asha Kamath; Vikram Shanbhogue; B C Pruthvi
Journal:  Avicenna J Med       Date:  2014-01

9.  Total Lymphocyte Count as surrogate marker for CD4 Cell Count in HIV-Infected Individuals in Gondar University Hospital, Northwest Ethiopia.

Authors:  Yitayih Wondimeneh; Getachew Ferede; Gizachew Yismaw; Dagnachew Muluye
Journal:  AIDS Res Ther       Date:  2012-07-15       Impact factor: 2.250

10.  Evaluating total lymphocyte count as a surrogate marker for CD4 cell count in the management of HIV-infected patients in resource-limited settings: a study from China.

Authors:  Jieqing Chen; Wei Li; Xiaojie Huang; Caiping Guo; Ran Zou; Qiuying Yang; Hongwei Zhang; Tong Zhang; Hui Chen; Hao Wu
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.